Cornea · 2021
Treatment of Dry Eye from Laser-Assisted In Situ Keratomileusis With Recombinant Human Nerve Growth Factor (Cenegermin).
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Habibi Roya N, Lee Michele D
Аннотация
PURPOSE: To describe 2 patients with neurotrophic keratitis after laser-assisted in situ keratomileusis surgery who were treated with recombinant human nerve growth factor (cenegermin) and the treatment course.
METHODS: Case series.
RESULTS: After an 8 week course of cenegermin, there was an improvement in visual acuity, corneal sensitivity, and ocular surface staining. However, these effects were short lived, and the disease regressed at subsequent follow-up visits.
CONCLUSIONS: Although recombinant human nerve growth factor seems to be effective in short term for neurotrophic keratitis secondary to laser-assisted in situ keratomileusis surgery, alternative dosing for patients with this patient population should be considered to achieve long-lasting resolution.
METHODS: Case series.
RESULTS: After an 8 week course of cenegermin, there was an improvement in visual acuity, corneal sensitivity, and ocular surface staining. However, these effects were short lived, and the disease regressed at subsequent follow-up visits.
CONCLUSIONS: Although recombinant human nerve growth factor seems to be effective in short term for neurotrophic keratitis secondary to laser-assisted in situ keratomileusis surgery, alternative dosing for patients with this patient population should be considered to achieve long-lasting resolution.